Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) - solution for injection - 400 iu - active: hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

Malta - engleski - Medicines Authority

medical logistics ltd no 8, ivo muscat azzopardi street, st julians stj 1905, malta - hepatitis a, virus, inactivated - suspension for injection in pre-filled syringe - hepatitis a virus (inactivated) 160 - vaccines

Malta - engleski - Medicines Authority

medical logistics ltd no 8, ivo muscat azzopardi street, st julians stj 1905, malta - hepatitis a, virus, inactivated - suspension for injection in pre-filled syringe - hepatitis a virus (inactivated) 25e3/0.5 millilitre(s) - vaccines

Malta - engleski - Medicines Authority

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - hepatitis a, virus, inactivated - suspension for injection in pre-filled syringe - hepatitis a virus (inactivated) 160 - vaccines

Malta - engleski - Medicines Authority

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - hepatitis a, virus, inactivated - suspension for injection in pre-filled syringe - hepatitis a virus (inactivated) 25e3/0.5 ml - vaccines

Tanzanija - engleski - Tanzania Medicinces & Medical Devices Authority

serum institute of india pvt. ltd. (siipl), india - hepatitis b virus - suspension for injection - 20mcg/ml

Tanzanija - engleski - Tanzania Medicinces & Medical Devices Authority

serum institute of india pvt. ltd. (siipl), india - hepatitis b virus - suspension for injection - 10mcg/ml

Tanzanija - engleski - Tanzania Medicinces & Medical Devices Authority

serum institute of india pvt. ltd. (siipl), india - hepatitis b virus - suspension for injection - 10ml

Tanzanija - engleski - Tanzania Medicinces & Medical Devices Authority

serum institute of india pvt. ltd. (siipl), india - hepatitis b virus - suspension for injection - o

Europska Unija - engleski - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.